slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 20,791-20,820
Pages 1,437
Rows per page 30
Arc
20,791-20,820 of 43,093
13
Includes a disclaimer about the reliability of cross-study comparisons.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
14
Includes two line charts with error bars representing mean +/- SD. LLOQ marked on the absolute chart.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Solution1 hit
17
The slide combines mechanistic biological data (Maun et al.) with clinical trial results (Cahill et al., NEJM) to justify targeting mast cells in severe asthma.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · Why NowLoop · Why Now1 hit
19
The slide uses a timeline-based visualization to show clinical progress and pairs it with financial status.Third Harmonic Bio | Investor Presentation Deck | 20 slides · Third Harmonic Bio
Pitch deck Investor relations Beat · The Ask1 hit
03
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle1 hit
04
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle1 hit
05
The slide provides a comprehensive overview of clinical and preclinical programs with detailed footnotes explaining specific drug statuses and licensing agreements.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · ProblemLoop · Golden Circle1 hit
07
The slide uses a split-layout: left side describes the drug product, right side lists clinical trial status for Fibromyalgia, Long COVID, and PTSD.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
Includes clinical trial status (RELIEF, RALLY, RESILIENT) and market demographics.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
Clinical trial design slide for Tonix Pharmaceuticals.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
Slide 10 of a corporate presentation deck.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide outlines a clinical trial protocol for TNX-102 SL in Long COVID patients.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
Includes disclaimer about non-approval and patent status.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
13
Slide 13 of a Tonix Pharmaceuticals presentation.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
Includes clinical trial status and mechanism of action highlights.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Slide provides a high-level summary of a pharmaceutical asset's profile and development roadmap.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
17
The slide uses a two-column layout to contrast the disease profile with the development program status.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
28
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · TeamLoop · Golden Circle1 hit
04
Includes a map of the Southeast US and a smaller map of the US highlighting the Southeast region.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · Problem1 hit
05
Includes a mix of big-number metrics on the left and comparative bar charts on the right.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
Includes non-GAAP operating performance metrics and a specific note on 1Q22 provision impact.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
07
The slide uses two tables to segment MSAs by size and compares population and household income growth against national benchmarks.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
The slide highlights deposit mix, cost of funds, and quarterly fluctuations in deposit balances.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
09
C&I includes commercial and industrial loans, owner-occupied CRE loans and Navitas (equipment finance) loans.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
10
The slide uses three line charts to compare UCBI performance against peers across Loans/Deposits, Tangible Common Equity, and Common Equity Tier 1 RBC.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
11
Includes a waterfall chart for TBV per share and a stacked bar chart for capital ratios.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
12
The slide uses a combination of a bar-line chart for historical revenue/margin and a waterfall chart for margin expansion drivers.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
13
The chart shows a stacked bar breakdown of income sources: Service Charges, Brokerage/Wealth Mgmt, Mortgage, Loan sale gains, and Other.United Community Banks | Results Presentation Deck | 24 slides · United Community Banks
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit